TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03226444
Drug: 0.005% Lacripep
DrugBank: Lacripep (DB18921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
Study: NCT03087019
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
Study: NCT03226444
Drug: 0.01% Lacripep
DrugBank: Lacripep (DB18921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
Study: NCT00781846
Drug: ridaforolimus
Normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, daily for 5 days/week
Study: NCT00781846
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT00976612
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400mg bid daily
Study: NCT02973711
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg BID
Study: NCT02973711
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib, 10, 15 or 20mg BID
Study: NCT04412291
Drug: Anakinra Prefilled Syringe
Normalized name: anakinra Prefilled Syringe
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
Study: NCT04412291
Drug: Tocilizumab Prefilled Syringe
Normalized name: tocilizumab Prefilled Syringe
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
Study: NCT02644486
Drug: High dosage Sevelamer Carbonate + Irbesartan
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
Study: NCT02644486
Drug: Low dosage Sevelamer Carbonate + Irbesartan
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
Study: NCT02644486
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 300mg/d
Study: NCT00585195
Drug: PF-02341066
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
Study: NCT00585195
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
Study: NCT00585195
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
Study: NCT00792181
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
Study: NCT02866539
Drug: Polyherbal capsule coccinia, bougainvillea, catharanthus
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A unique combination of 3 herbs that lower blood sugars
Study: NCT02533570
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01937156
Drug: Granisetron Hydrochloride Tablet
Normalized name: Granisetron Hydrochloride Tablets
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
Study: NCT00423930
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01905137
Drug: Intervention-Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
Study: NCT00758277
Drug: levetiracetam (Keppra)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levetiracetam daily application 1500-2000 mg
Study: NCT00651469
Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Normalized name: drospirenone
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
Study: NCT01324596
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemoimmunotheraphy
Study: NCT00351520
Drug: Miltefose
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02390050
Drug: Bexagliflozin tablets
Normalized name: bexagliflozin
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
Study: NCT02390050
Drug: Bexagliflozin tablets, placebo
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
Study: NCT01522469
Drug: Crenolanib Besylate (CP-868,596-26)
Normalized name: CP
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
Study: NCT03705832
Drug: Ginger Extract
Normalized name: ginger extract
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2gm Capsule of Ginger extract
Study: NCT01050790
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
Study: NCT01880528
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01825733
Drug: ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
Study: NCT00750802
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg tablet, oral single-dose
Study: NCT00918983
Drug: NX-1207
Normalized name: NX-1207
DrugBank: NX-1207 (DB05493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection of 2.5 mg NX-1207
Study: NCT04517292
Drug: Eribulin,cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
Study: NCT01825733
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
Study: NCT00297336
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80 patients with diagnosed with migraine
Study: NCT01122160
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
Study: NCT04517292
Drug: Gemcitabine,cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
Study: NCT03337451
Drug: OPN-305
Normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive study drug every 4 weeks
Study: NCT00361218
Drug: open-label selective serotonin reuptake inhibitor (SSRI)
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
Study: NCT06081699
Drug: TNP-2198
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00038766
Drug: semapimod
Normalized name: Semapimod
DrugBank: Semapimod (DB12094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: semapipmod 60 mg IV x 5 days
Study: NCT00038766
Drug: semapimod
Normalized name: Semapimod
DrugBank: Semapimod (DB12094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 30 mg x 5 days
Study: NCT00904046
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg orally daily for 6 months
Study: NCT04058366
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT00484289
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
Study: NCT01974687
Drug: Uprifosbuvir
Normalized name: Uprifosbuvir
DrugBank: Uprifosbuvir (DB15206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
Study: NCT01974687
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
Study: NCT00284687
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PO Artesunate
Study: NCT00972985
Drug: modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet, 100 mg, single acute dose
Study: NCT00972985
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 20 mg, single acute dose
Study: NCT00972985
Drug: lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 1 mg, single, acute dose
Study: NCT01327859
Drug: Prior Donepezil 5mg
Normalized name: donepezil hydrochloride 5 MG
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
Study: NCT00626678
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
Study: NCT01184144
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone, 30 mg, by mouth daily for 2 weeks
Study: NCT01336803
Drug: Feraheme
Normalized name: Feraheme
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg/kg by intravenous (IV) administration
Study: NCT00452062
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02634489
Drug: Tamsulosin HCl
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02634489
Drug: Solifenacin Succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02634489
Drug: EC905
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01497600
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study: NCT02990221
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
Study: NCT00807222
Drug: lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
Study: NCT04208945
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500000 units of inhaled colistin three times daily for 10 days
Study: NCT00975767
Drug: MGCD265+erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MGCD265 and erlotinib administered daily
Study: NCT00975767
Drug: MGCD265+docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MGCD265 administered daily; docetaxel administered once every 3 weeks
Study: NCT00911963
Drug: VCH-222 or matching placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsule, oral, 4 doses once daily or twice daily, 3 days
Study: NCT00911963
Drug: VCH-222 or matching placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
Study: NCT00911963
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
Study: NCT00802841
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplied as 200 mg tablets
Study: NCT00802841
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Supplied as 100 mg and 400 mg tablets
Study: NCT04591431
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT00309335
Drug: Phentolamine Mesylate (NV-101)
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04591431
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Vismogedib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TT arm
Study: NCT04209686
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV
Study: NCT04209686
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg
Study: NCT04209686
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV
Study: NCT00987792
Drug: Moxifloxacin (Avelox, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospitalized patients receiving Avelox according to local drug information
Study: NCT02590133
Drug: Recombinant Human Endostatin Injection (Endostar)
Normalized name: hyaluronidase, human recombinant Injection
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study: NCT04591431
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Pralsetinib
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT arm
Study: NCT04591431
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TT arm
Study: NCT04591431
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TT arm
Study: NCT00480376
Drug: ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02590133
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total